SEARCH:      Monitor Keywords |  Custom RSS

Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof October categorized by USPTO classification 10/11

20110263815 - Triazole macrocycle systems: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.... Agent: Aileron Therapeutics, Inc., A Delaware Corporation

20110263816 - Metallopeptide catalysts: This application provides a metallopeptide catalyst comprising dirhodium bound to one or more carboxylate residues of a peptide, protein or peptidomimetic. These stable metallopeptides can achieve structure-selective protein modification though molecular recognition.... Agent: Rice University

20110263817 - Metal-binding compounds and uses therefor: The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further... Agent:

20110263818 - Peptidic constructs with amino acid surrogates: e

20110263819 - Simplified one-pot synthesis of [18f]sfb for radiolabeling: A non-aqueous single pot synthesis of [18F]SFB is set forth. The [18F]SFB produced with this method is then used, for example, to label a peptide or an engineered antibody fragment (diabody) targeting human epidermal growth factor receptor 2 (HER2) as representative examples of labeled compounds for use as an injectable... Agent: The Regents Of The University Of California

20110263820 - Antibodies and processes for preparing the same: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to... Agent: Taiga Biotechnologies, Inc.

20110263822 - Composition for the prophylaxis and treatment of hbv infections and hbv-mediated diseases: The present invention is a composition that comprises at least two hepatitis B virus surface antigens (HBsAgs), fragments thereof and/or nucleic acids encoding them, the HBsAgs differing in HBV genotype in the S region and/or pre-S1 region and the composition containing no HBV core antigen (HBcAg) or nucleic acid encoding... Agent: Rhein Biotech Gesellschaft Fur Neue Biotechnologische Prozesse Und Produkte Mb

20110263823 - Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers: This invention relates to the use of mixed mode chromatography for purification of a protein from a mixture containing other materials, including fragmented or aggregated antibodies, host cell proteins, DNA, endotoxin, and/or virus. This invention further relates to the integration of such a method into a multi-step procedure with other... Agent: Bio-rad Laboratories, Inc.

20110263821 - Prognosis and risk assessment in stroke patients by determining the level of marker peptides: The present invention relates to a method for prognosis of an outcome or assessing the risk of a patient having suffered a stroke or a transient ischemic attack, comprising the determination of the level of at least one marker peptide in said sample said marker peptide selected from the group... Agent: B.r.a.h.m.s. Gmbh

20110263824 - Modified biotin-binding protein: e

20110263825 - Anti-cd20 monoclonal antibodies: It is intended to provide a monoclonal antibody having a growth inhibitory activity against a cell having a human CD20 antigen which is produced by using, as immunogens, a human B cell line expressing the human CD20 antigen and a cell line originating in a non-human animal, which is different... Agent: Osaka University

20110263826 - Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals: The present invention provides antibodies which bind selectively to hair of animals and an antibody based drug delivery system in which a particular formulation can be directed to animal hair. This is driven by the need of increasing the effective period of therapeutics for animal ectoparasites treatment, reducing the toxicity... Agent: Bayer Schering Pharma Aktiengesellschaft

20110263829 - Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same: Disclosed are a cell-penetrating, base sequence-specific, nucleic acid-hydrolyzing antibody, a method of preparing the same, and a pharmaceutical composition comprising the same. The antibody can be prepared by modifying a particular site of a cell-penetrating, nucleic acid-hydrolyzing antibody which lacks substrate specificity to impart sequence specificity thereto without alteration in... Agent: Ajou University Industry Academic Cooperation Foundation

20110263827 - Dual variable domain immunnoglobulins and uses thereof: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.... Agent: Abbott Laboratories

20110263828 - Methods for modifying human antibodies by glycan engineering: Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc... Agent: Academia Sinica

20110263830 - Process for the modulation of the antagonistic activity of a monoclonal antibody: The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target... Agent:

20110263831 - Nuclear factor kappab inducing factor: The present invention is directed to nuclear factor κB (NFκB)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NFκB. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are... Agent: Aventis Pharmaceuticals Inc.

20110263832 - Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides: The present invention generally provides methods for the site-specific modification of peptides, polypeptides, and proteins, e.g., granulocyte macrophage colony-stimulating factor, human superoxide dismutase, annexin, leptin, antibodies and the like, cytokines and chemokines, at their N-termini and at sites at which unnatural aminoacids have been introduced along the protein framework. The... Agent:

20110263833 - Compositions for isolating a target analyte from a heterogeneous sample: The invention generally relates to compositions that include sets of magnetic particles, members of each set being conjugated to an antibody specific for a pathogen.... Agent: Nanomr, Inc.

20110263835 - Recombinant nell protein production: The present invention provides a method and system for producing a NELL protein. The method and system comprise a CELL encoding a NELL protein or peptide and a non-insect secretory signal peptide.... Agent: The Regents Of The University Of California

20110263834 - Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels: This invention is directed to methods for removing, preferably simultaneously and in one step, multiple impurities form crude culture samples, and, in particular, the removal of media components, protein, nucleic acids, lipids, and lipopolysaccharides to ultralow levels. Preferably the purification process comprises: (1) binding of the target substance containing one... Agent: Serum Institute Of India, Ltd.

20110263836 - Method for reduction of light-induced yellowing of lignin-containing material: A method for treating lignin-containing fibrous material to reduce its susceptibility to yellowing generally includes enzymatically stabilizing the lignin of the material with an oxidizing agent capable of oxidizing phenolic or similar groups, which may undergo reactions conductive to the formation of colored sites on the fibers, and treating the... Agent: Kemira Oyj

20110257364 - Process for purifying glycopeptide phosphonate derivatives: Disclosed are methods of purifying glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups that are useful as antibacterial agents. The methods include contacting a solution of the glycopeptide derivatives with a polystyrene-containing resin, eluting the resin with an aqueous solution, and isolating... Agent: Theravance, Inc.

20110257365 - Cyclin based inhibitors of cdk2 and cdk4: Structural and functional analysis of peptide inhibitor binding to the cyclin D1 groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of... Agent: University Of South Carolina

20110257367 - Allogeneic vaccine and methods to synthesize same: This invention provides a genetically manipulated cell useful for treating or preventing a malignant tumor in a patient which: (a) expresses at least one immunomolecule selected from the group consisting of cytokines, adhesion molecules, costimulatory factors, tumor associated antigens and tumor specific antigens; and (b) is allogeneic to the patient.... Agent: Sloan-kettering Institute For Cancer Research

20110257366 - Method for screening candidate compounds for antitumor drug: Investigation on the frequency of FLT3/ITD found in various blood cancers has revealed that the frequency is high in acute myeloblastic leukemia in particular. Studies on the effects of FLT3/ITD in the blood cell lines revealed that the tyrosine residues in FLT3/ITD is constitutively phosphorylated in these cell lines and... Agent: Chugai Seiyaku Kabushiki Kaisha

20110257368 - Purification of recombinantly produced interferon: The present invention provides a method for separating desired interferon isoforms from undesired interferon isoforms that involves subjecting the isoforms to anion exchange column chromatography and a biphasic elution procedure. A strong elution solution is used in the first elution phase to facilitate elution of the desired isoform from the... Agent: Schering Corporation

20110257369 - Methods for removing nicotine and other alkaloids from soluble leaf proteins in solanaceous and other plant species: Described herein is a process for removing nicotine and other alkaloids from plant leaf proteins. The plant leaf proteins may be derived from tobacco }Nicotiana tabacum) and other solanaceous and toehr green leaf plants, both non-transgenic and transgenic. The present invention provides efficient techniques for removing nicotine and toehr alkaloids... Agent: University Of Maryland

20110257370 - Immunoglobulin purification: The current invention reports a method for purifying an immunoglobulin, wherein the method comprises applying an aqueous, buffered solution comprising an immunoglobulin in monomeric, in aggregated, and in fragmented form to an anion exchange chromatography material under conditions whereby the immunoglobulin in monomeric form does not bind to the anion... Agent:

20110257372 - Immunoglobulins devoid of light chains: There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains.... Agent: Vrije Universiteit Brussel

20110257371 - Methods of treating chronic pain: Methods of Treating Chronic Pain The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of chronic pain and/or symptoms of chronic pain, and to a method of treating and/or preventing chronic pain and/or symptoms of chronic pain using an anti-CGRP antibody.... Agent: Pfizer Limited

20110257373 - Ligands that have binding specificity for dc-sign: The present invention disclosure provides an anti-dendritic cell-specific ICAM-3 grabbing non-integrin (DC-SIGN; CD209) immunoglobulin single variable domain. Polypeptides, ligands and compositions comprising such anti-DC-SIGN immunoglobulin single variable domains are also described along with nucleic acids encoding such immunoglobulins and vectors and host cells for expression. The invention disclosure further relates... Agent:

20110257374 - Novel reagents for directed biomarker signal amplification: Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development... Agent: Sirigen, Inc.

20110257375 - Increasing efficiency of nucleic acid delivery in vivo using targeting conjugates: Described herein is the use of antibody-based delivery agents to target and deliver nucleic acid agents into specific cell types. Herein, we describe methods used that improve the ability of conjugates that load over 3 siRNA per conjugate and target siRNA to cells expressing the appropriate cell surface antigens. We... Agent:

20110257376 - Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo: Methods are provided for labeling cellular glycans bearing azide groups via fluorescent labeling comprising Cu(I)-catalyzed [3+2] cycloaddition of a probe comprising alkynyl group. Generation of fluorescent probes from a nonfluorescent precursor, 4-ethynyl-N-ethyl-1,8-naphthalimide, by Cu(I)-catalyzed [3+2] cycloaddition of the alkyne group of the probe to an azido-modified sugar are provided. Incorporation... Agent: Academia Sinica

20110257377 - Covalently linked complexes of hiv tat and env proteins: Complexes of HIV Env and Tat proteins are advantageous as immunogens compared to Tat or Env alone, but they may dissociate when combined with a vaccine adjuvant. To avoid dissociation, complexes of Env and Tat are stabilized by the use of covalent cross linking. The extent of cross linking is... Agent:

20110257378 - Aqueous two phase extraction augmented precipitation process for purification of therapeutic proteins: The invention relates to an aqueous two phase extraction (ATPE) augmented precipitation process, which may be used to recover and also partially purify therapeutic proteins, including monoclonal antibodies from a crude multi-component mixture. The process involves the formation of a forward extraction PEG-Phosphate ATPE system in which the target product... Agent: Ge Healthcare Bio-sciences Ab

20110251372 - Process for the production of bivalirudin: The present invention relates to a process for the production of bivalirudin, a 20-mer peptide of formula H-D-Phe1-Pro-Arg-Pro-Gly5-Gly-Gly-Gly-Asn-Gly10-Asp-Phe-Glu-Glu-Ile14-Pro-Glu-Glu-Tyr-Lee-OH (I) via a convergent five-fragment synthesis, and to several peptide intermediates thereof.... Agent:

20110251373 - Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from... Agent: Vlaams Interuniversitair Instituut Voor Biotechnologie

20110251374 - Antibody purification method: Provided is a purification method that purifies an antibody to a high purity, effectively removes antibody polymer (or aggregate), and improves antibody recovery rate. An antibody purification method including a step for treating a solution containing an antibody by mixed mode chromatography in the presence of an amino acid is... Agent:

20110251375 - Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions: Immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind, obtained from display libraries.... Agent: F-star Biotechnologische Forschungs-und Entwicklungsges.m.b.h.

20110251376 - Mammalian tumor susceptibility genes and their uses: TSG101 is a tumor susceptibility gene whose homozygous functional knock out in fibroblasts leads to transformation and the ability of these cells to form metastatic tumors in nude mice. The cellular transformation that results from inactivation of TSG101 is reversible by restoration of TSG101 function. Decreased expression of TSG101 is... Agent:

20110251377 - Ionic liquid systems for the processing of biomass, their components and/or derivatives, and mixtures thereof: Disclosed herein are compositions and methods that involve ionic liquids and biomass. In one aspect, the disclosure relates to ionic liquid systems for the processing of biomass, their components and/or derivatives, and mixtures thereof.... Agent: The Board Of Trustees Of The University Of Alabama

20110245458 - Peptide nucleic acid monomers and oligomers: Disclosed is a peptide nucleic acid monomer as well as a corresponding peptide nucleic acid molecule. The monomer comprises a terminal amino group and a terminal group A. The terminal amino group and the terminal group A are connected by an aliphatic moiety. The main chain of this aliphatic moiety... Agent: Nanyang Techonological University

20110245459 - Processes for intermediates for macrocyclic compounds: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with... Agent:

20110245460 - Solvent resistant diafiltration of peptides, pna or oligonucleotides: According to the present invention, there is provided a process for the preparation of a first compound selected from peptides, oligonucleotides and peptide nucleic acids. The process comprises synthesising the first compound and then separating the first compound formed in step (i) from a second compound, which is a reaction... Agent: Imperial Innovations Limited

20110245461 - Methods for determining the retention of peptides in reverse phase chromatography using linear solvent strength theory: The present disclosure relates to methods for separating or isolating a peptide using reverse phase chromatography. The disclosure also relates to methods for calculating or determining the slope S of a peptide, wherein S is defined according to the Linear-Solvent-Strength equation log k=log k0−S*φ. Also provided are a set of... Agent:

20110245462 - Non-fluorescent quencher compounds and biomolecular assays: e

20110245463 - Apparatus and method for structure-based prediction of amino acid sequences: The present invention provides methods and apparatus for analyzing a protein structure.... Agent: Algonomics N.v.

20110245464 - Highly thermostable fluorescent proteins: Thermostable fluorescent proteins (TSFPs), methods for generating these and other stability-enhanced proteins, polynucleotides encoding such proteins, and assays and method for using the TSFPs and TSFP-encoding nucleic acid molecules are provided. The TSFPs of the invention show extremely enhanced levels of stability and thermotolerance. In one case, for example, a... Agent: Los Alamos National Security, LLC

20110245465 - Methods for detection of methyl-cpg dinucleotides: The invention provides methods for enriching methyl-CpG sequences from a DNA sample. The method makes use of conversion of cytosine residues to uracil under conditions in which methyl-cytosine residues are preserved. Additional methods of the invention enable to preservation of the context of me-CpG dinucleotides. The invention also provides a... Agent: Brookhaven Science Associates, LLC

20110245466 - Method of production of polyanionic drug-carrier conjugates: The invention concerns the method of production of a polyanionic macromolecule which is a protein built, among others, form polar amino acids (such as lysine, arginine, aspartic acid, glutamic acid), characteristic in that, that as a result of the reaction between amine groups and the cyclic anhydride of dicarboxylic acid,... Agent:

20110245467 - Rapid, sensitive and quantitative methods for tissue and cell-based proteomics via consecutive addition of quantifiable extenders: Methods, systems and kits are provided for detecting and quantifying multiple immunogens in a sample via consecutive addition of quantifiable extenders to immunogen bound complexes of immunogen binding agent attached to a DNA containing an RNA polymerase promoter.... Agent: Trustees Of The University Of Pennsylvania

20110245468 - B7-h5, a costimulatory polypeptide: B7-HS costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.... Agent: Mayo Foundation For Medical Education And Research

20110245469 - Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives: Disclosed are human relaxin-Fc fusion proteins having an increased serum half-life, polynucleotides encoding the same, and intermediates formed during the fusion protein biosynthesis. The fusion proteins may include a linker portion or other sections as well. Suitable fusion proteins are also those predicted to have the same effect as human... Agent: Athena Discovery, Inc.

20110245470 - Immunoglobulins: The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM... Agent: Glaxo Group Limited

20110245471 - Nuclear factor kappab inducing factor: The present invention is directed to nuclear factor κB (NFκB)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NFκB. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are... Agent: Aventis Pharmaceuticals Inc.

20110245472 - Method for the mass production of immunoglobulin constant region: Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing... Agent: Hanmi Holdings Co., Ltd.

20110245473 - Anti-il-6 receptor antibody: The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under... Agent: Chugai Seiyaku Kabushiki Kaisha

20110245474 - Methods for g-csf production in a pseudomonas host cell: The present invention relates to the field of recombinant protein production in bacterial hosts. It further relates to expression of soluble, active recombinant protein by using secretion signals to direct the protein to the periplasmic space of a bacterial cell. In particular, the present invention relates to a production process... Agent: Pfenex Inc.